cancer-cells-3d-illustration-bea2
invIOs goes live with unique cell therapy platform and clinical-stage immuno-oncology pipeline
invIOs (innovative Immuno-Oncology) GmbH, a privately held biotechnology company developing novel therapies for cancer, is pleased to announce it will commence operations on 1 January 2022. invIOs, a fully owned subsidiary of APEIRON Biologics AG has been assigned APEIRON’s innovative cancer immunotherapy activities and all related clinical and preclinical R&D projects. invIOs’ CEO Peter Llewellyn-Davies...
December 16, 2021
No Comments
inhal-1110x540
APEIRON Biologics commences clinical COVID-19 trial with inhaled APN01
Inhalation of APN01 to directly target SARS-CoV-2 virus in respiratory tract, the lung and tissue itself Primary objective is to evaluate safety and tolerability of inhaled APN01 Phase 1 trial to enroll about 40 healthy volunteers Additional US Phase 2 trial with intravenous administration of APN01 Press release (EN) | Presseaussendung (DE)
October 12, 2021
No Comments
UE_Invest_27_11_2017CLAU9035
APEIRON Biologics launches next clinical trial with innovative cancer therapy APN401

Important development step for promising cell therapy Paradigm shift in cancer treatment: process developed by APEIRON uses immune system to treat solid tumors Innovative new manufacturing and treatment process enables outpatient treatment within one day from cell collection to reinfusion Phase Ib clinical trial evaluates immunological effects as well as safety and tolerability of APN401…

July 6, 2021
No Comments
20210601_1110x540
APEIRON Biologics Announces Changes to Management and Supervisory Boards

Management Board to be expanded by Romana Gugenberger, PhD, as Chief Medical & Scientific Officer (CMSO) and Andreas Gerber, PhD, as Chief Operating Officer (COO) Prof. Josef Penninger moves from the Supervisory Board to the newly created Scientific Advisory Board, which he will build up and lead as Chairman Additional pre-clinical data show highly promising…

June 1, 2021
No Comments
image001-1110x540
APEIRON Biologics’ APN01 selected for large-scale US trial in COVID-19
APEIRON ́s APN01 to participate in US Phase 2 COVID-19 trial ACTIV-4d RAAS Further clinical study in preparation with inhalative drug delivery of APN01 to directly target respiratory tract and lung tissue Additional pre-clinical data show highly promising results with APN01 in various mutation variants Financing round planned to secure funding of further upcoming development...
May 19, 2021
No Comments
3d rendering of virus cells
APEIRON’s APN01 shows clinical benefits for severely ill COVID-19 patients in phase 2 trial
Treatment was safe and well tolerated and no drug-related severe adverse events were observed Significant improvement in mechanical ventilator-free Days and reduction in viral RNA load observed Biomarker development supports APN01’s mode of action against SARS-CoV-2 Investigators and experts recommend further development of APN01 in COVID-19 Press release (EN) | Presseaussendung (DE)
March 12, 2021
No Comments
coronavirus-1110x540
APEIRON Biologics: Patient recruitment completed in Phase II COVID-19 Clinical Trial of APN01
Results of the double-blind, placebo-controlled trial expected in Q1 2021 Preparations for rolling Marketing Authorization Application in Europe commenced Trial results to confirm unique triple mode of action to prevent infection, organ injury and inflammation Press release (EN) | Presseaussendung (DE)
December 4, 2020
No Comments
UE_Invest_27_11_2017CLAU8062-1110x540
APEIRON Biologics AG and Domainex Ltd announce the expansion of their partnership to progress targeted cancer immune therapy drug discovery
Integrated lead optimisation to advance APEIRON’s Cbl-b inhibitor development programme APN431 Inhibitors discovered at Domainex via virtual and fragment screening Press release (EN) | Presseaussendung (DE)
November 9, 2020
No Comments
Copyright © 2022 APEIRON Biologics AG. All rights reserved.
A member of